Date: 2015-01-19
Type of information: Financing round
Company: Sensorion (France)
Investors: Innobio (France) Inserm Transfert Initiative (France)
Amount: €4 million
Funding type: financing round
Planned used: This new funding will allow Sensorion to begin a phase 1 clinical trial of its first drug candidate for the symptomatic treatment of severe vertigo, dizziness or tinnitus. Sensorion has developed its scientific expertise in the field of hair cells, which are neurosensory cells that are crucial for the inner ear to operate correctly. The company has developed a technological platform enabling it to develop and test new treatments for all inner ear disorders, both symptomatic and anti-lesional. Two initial drug candidates chosen using the Sensorion platform, one for treating symptoms during bouts of acute vertigo or tinnitus and the other for treating progressive lesions in the inner ear, are about to enter the clinical phase.
This funding round will be used for the first drug candidate, SENS-111, aimed at treating bouts of vertigo or tinnitus, will now be able to begin its 1b clinical phase during the 1st quarter of 2015. The sum raised will also open the way for the selection of a second drug candidate within a distinct programme aimed at treating lesions in the inner ear.
Others: * On January 19, 2015, Sensorion, a biotech specialising in the treatment of inner ear diseases, announced that it has completed a new funding round from its longstanding shareholders, Innobio and Inserm Transfert Initiative, for an amount of up to €4 million depending on the achievement of clinical milestones, thus taking the total funds raised since its creation in 2009 to €10 million.
Therapeutic area: Otorhinolaryngology
